Share Name Share Symbol Market Type Share ISIN Share Description
Salvarx Group Plc LSE:SALV London Ordinary Share IM00BZ4SS228 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.50 0.00 0.00 0.00 0.00 - 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -0.5 1.0 4.5 2

Salvarx Share Discussion Threads

Showing 251 to 274 of 500 messages
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
DateSubjectAuthorDiscuss
15/8/2018
10:51
BTW,I won't be voting for this sell-off anytime soon. I've always been a long-term investor.Fig.
fig1
15/8/2018
09:18
Block capitals were merely to emphasise the change I made. I'm not clever enough to master 'strike through' or 'bold' on ADVFN. I don't believe I have lost the argument. Actually, I didn't realise there was an argument. All along I was just seeking clarity. You came on here acting the big man saying I was dim because I couldn't understand a simple transaction and that perhaps I should buy Premium Bonds instead. Then it turns out I was right. this is a murky deal. Much of the structure makes no sense. So you get all defensive. You could give your magical insight by answering my 5 questions in my post 197 ? I am a Salvarx holder. At 34p from 12 months or so ago.
dexdringle
15/8/2018
08:52
No need to shout Dex, sure fire way of showing you have the lost the argument. If you think this deal is a bad one then sell the SALV shares you own and be thankful of the recent uplift. If on the other hand you do not own any you have now talked yourself out of buying so it's time to move on and use your limited intellect to assess other situations that are also utterly unproductive.
bigego
15/8/2018
08:49
bandflex but... "Concurrent with the Disposal, it is proposed that not less than 656,399,142 of the Consideration Shares (the "Demerger Shares") will be transferred to Shareholders on a pro-rata basis, as explained below (the "Demerger"). Of the balance of the Consideration Shares, it is proposed that 40,692,698 Consideration Shares will be transferred to Option Holders in consideration of the purchase of their Redemption Options (the "Option Redemption") (as explained below), and up to 60,851,944 Consideration Shares will be retained by the Company". Does this not mean that of the 100M shares not distributed to ordinary shareholders 40M go to the warrant (option ?) holders and 60M are retained then?
dexdringle
15/8/2018
08:36
For the less than positive posters.When the next intensity news hits what do you think that will do to the share price here?
glenbo1
15/8/2018
08:20
Dexdringle SALV would distribute the retained 60m shares to warrant holders at 18 shares per warrant, there are about 3.2m warrants, so SALV would be left with around 2.5m Portage shares.
bandflex
15/8/2018
08:18
Jim M has an interest in both investments, being a cynic i'm sure that any transaction here is for the benefit of JM & Co rather than Salvx shareholders more broadly They'll be some tax advantage for those holders or some other factor behind this......
kristini2
15/8/2018
08:15
Good question bandflex. Best ask Bigego - he knows everything...... “Stig, good to see Dex may have found his spare brain cell and appears to have SPOTTED THE FLAW IN MY NAIVE ASSESSMENT OF THE SITUATION” There we are bigego - I've fixed that for you...
dexdringle
15/8/2018
08:11
Portage shares are only showing a value of $0.10 because they have been suspended. Once they come out of suspension then you can value the bid, at the moment that is not possible, and theirs still no date for a Portage shareholder vote. It's convenient that they suspend Portage but not SALV, it allows some big players to dump into the rise and avoid being caught out by a possible Portage share collapse when suspension is finally lifted. Why didn't they suspend SALV until both could be traded.
bandflex
15/8/2018
07:56
Stig, good to see Dex may have found his spare brain cell and appears to have worked out the actual true numeric aspect of the deal, wonder if he got a small child to help? However it appears those three brain cells cannot think more laterally. I neither have the time or desire to help him further.
bigego
15/8/2018
07:42
Thanks fig1. Glad I'm not the only one not wearing rose tinted glasses ! Bigego and The Stig are all excited about it. Then again, it is school holidays....
dexdringle
15/8/2018
07:36
.....of course,it could be designed to smoke out a counter-bid from another interested (but,as yet,undisclosed)party.Just speculating.....
fig1
15/8/2018
07:31
All good points Dex. Seems an overly (deliberately)complex way to conduct things.I'm a long term holder but with no facility to trade Canadian shares(of any size).Feels a bit like small guys like me are being maneuvered out of the picture just before big news breaks.I hope I'm wrong. Fig.
fig1
15/8/2018
07:22
Okay, I'll do it then: 1. Salvarx Group (the company in which we own shares) is selling its only asset, a 94% stake in Salvarex Limited (which in turn owns all of the sub assets), to Portage Biotech. 2. Portage Biotech is paying around £60 million Salvarx Limited by issuing new 757 million new shares thought to be worth around US 10 cents (8p) each. 3. On Monday, Salvarx Group had a market cap of around £17 million - so the £60 million bid value represents a 3.5x multiple (hence the 250% PREMIUM to the current price). 4. Immediately after the deal Salarx Group will own 757 million Portage shares (allegedly worth £60 million) and a bit of cash. Each Salvarx Group share would therefore be worth around £1.76. 5. Salvarx Group will then distribute 656 million (85%) of the portage shares to Salvarx Group shareholders at a rate of around 18 for every 1 Salvarx Group share they own. 6. Salvarx Group will then be a shell company which has a bit of cash and, inexplicably, a retained holding of 60 million Portage shares worth around £5 million. So, the old Salvarx Group in which we will continue to own the same number of shares should have a value of around 15p a share. Questions: a) If the deal makes each Salvarx share worth £1.91 (points 4 and 6 above), why are they now trading at 65p? b) If the Salvarx Limited assets are so valuable why is Salvarx Group selling? c) Why are Portage not simply launching a takeover for the whole Salvarx Group at, say, 80p a share rather than buying a sub asset for twice that amount? d) Why does Salvarx Group not simply hold on to the 757 million Portage shares like it did the Salvarx Limited shares? e) What are the chances of Portage shareholders voting for a massive dilution so they can, on the face of it, massively overpay for a ‘pie in the sky’ British asset? f) Why on earth would I want to hold shares in a penny share biotech business listed in Canada? Something is not right here……….
dexdringle
15/8/2018
01:19
Daily Mail Market Report "But shareholders in Salva Rx, a biotechnology firm which attempts to create treatments that boost the body’s natural defences to fight cancer, were in for a more positive surprise. Shares shot up 43.5 per cent, or 19.4p, to 64p as the company announced it was selling its subsidiary to Canada-listed Portage Biotech."
the stigologist
15/8/2018
00:28
10 products list that on US markets and you are looking at a valuation in the 'hundreds of millions' if not $1bn+ As I said before. Will be holding this for the medium term. These guys are serious players, who've delivered for shareholders before and bigtime. It's actually a Double Whammy. We get the in-specie distribution and SALV becomes a cash shell which could do it's own RTO.
the stigologist
15/8/2018
00:27
This gets better and better ! Portage are not hanging around. It is a reverse takeover, they will also have a consolidation (allowing US Investors to buy). I expect this will become a very big company. Note their comment about buying before an imminent inflection point for valuation uplift. "Declan Doogan, C.E.O. of Portage, remarked, "Since we completed the distribution of Biohaven shares, we have been looking for other exciting undervalued opportunities with near term inflection points. The acquisition of SalvaRx Limited represents the next evolution of Portage as we acquire interest in 10 products in the exciting area of immuno-oncology led by a top class team. Portage is now poised to advance several products to clinical proof of concept and hopefully take advantage of strong capital markets and increased levels of pharma mergers and acquisitions to bring yet more returns to our shareholders.""
the stigologist
14/8/2018
22:32
dex if you need to know how to use a simple instrument such like the humble calculator you should not be investing in shares. Suggest you go and buy some Premium Bonds and leave the junior markets to those who can. Twelve hours in and he cannot do a few simple calculations, no hope I am afraid.
bigego
14/8/2018
18:16
It's okay. bigego will be along shortly to explain to us all how simple the whole thing is......
dexdringle
14/8/2018
16:52
Not a lot of action on the CES either - last traded Aug 9. You really want 18 of these shares per SALV? hTTp://thecse.com/en/listings/life-sciences/portage-biotech-inc Last news release June 7 2018.
typo56
14/8/2018
16:22
The news has not been released on the CES either as far as I can tell, and the trading halt is still in place, so no way to gain reaction of Portage shareholders. Its all very odd. 250% - If something is too good to be true, then it probably is.
bandflex
14/8/2018
16:01
I find it strange that I can't find any mention of today's announcement here, given it would involve the issue of 758m shares. This is the right site? hTTps://www.portagebiotech.com/
typo56
14/8/2018
15:53
The RNS talks of the share offer being valued at US$1.80, not C$1.80. "Based on the Portage share price of US$0.10 (being the price of the last trade on the OTC on 10 August 2018)".
typo56
14/8/2018
15:25
The share offer, valued at C$1.80 a share, translates to 108p. Portage Biotech last traded on 9 August and is valued at just C$28 million. However it enjoyed a spectacular success at the end of last year distributing shares in Biohaven, one of the most successful biotech 1POs in New York. SalvaRx CEO Ian Walters loathed AIM. He is on the board of Portage. Clearly today's news is being treated with huge suspicion given the price reaction but biotech is much better understood on the other side of the Atlantic and should be better valued accordingly.
wiseacre
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
Your Recent History
LSE
SALV
Salvarx
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200121 15:30:41